食管保护放疗用于复杂性脊柱转移瘤的III期随机试验
这项双中心、单盲、III期随机试验纳入188例颈胸段复杂性脊柱转移瘤患者,比较食管/咽保护VMAT/IMRT与标准VMAT/IMRT。意向治疗分析显示两组峰值吞咽困难无差异(p=0.20),但符合方案分析显示显著差异(p=0.50)。食管剂量学参数与「严重或更差」吞咽困难相关。
要点
- 意向治疗分析中食管保护VMAT/IMRT未降低峰值吞咽困难(p=0.20)。
- 符合方案分析中峰值吞咽困难差异显著(p=0.50)。
- 食管剂量参数(D0.027cc-D5cc、V15Gy-V25Gy)与严重吞咽困难相关。
核心结论
- 食管保护VMAT/IMRT在意向治疗分析中未降低峰值吞咽困难,但在符合方案分析中显示显著获益。
- 较高的食管剂量和较大的照射体积与「严重或更差」吞咽困难风险相关,提示食管/咽保护放疗可能尤其使接受高剂量、大野照射的患者获益。
研究设计与样本
- 双中心、单盲、III期随机试验(NCT05109819),纳入成人颈胸段(C1-T12)复杂性脊柱转移瘤接受1-10次放疗的患者。
- 随机分配至常规或食管/咽保护VMAT/IMRT,共188例随机(标准组92例纳入、60例分析;食管保护组96例纳入、70例分析)。
主要发现
- 任何级别吞咽困难发生率:标准组64%,食管保护组55%。
- 意向治疗分析:峰值吞咽困难无差异(p=0.20),步行功能无差异(p=0.30)。
- 符合方案分析:峰值吞咽困难差异显著(p=0.50)。
- 剂量学参数(D0.027cc-D5cc、V15Gy-V25Gy)与「严重或更差」吞咽困难相关。
关键数值与推荐
- 食管剂量学参数D0.027cc-D5cc和V15Gy-V25Gy与「严重或更差」吞咽困难相关。
临床怎么用
- 对于接受高剂量、大野照射的复杂性脊柱转移瘤患者,食管/咽保护VMAT/IMRT可能减少严重吞咽困难风险。
- 需关注食管剂量学参数(D0.027cc-D5cc、V15Gy-V25Gy)以评估严重吞咽困难风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients receiving palliative radiotherapy (RT) for complicated spinal metastases in the cervical and thoracic spine may develop dysphagia due to esophageal and pharyngeal irradiation. This phase III trial investigated if esophagus/pharynx-sparing VMAT/IMRT could reduce patient-reported peak dysphagia without affecting ambulatory function compared to standard VMAT/IMRT. METHODS: This dual-center, single-blind, phase III trial (NCT05109819) randomized adult patients with complicated spinal metastases (C1-T12) receiving 1-10 fraction RT to either conventional or esophagus/pharynx-sparing VMAT/IMRT. Patient-reported outcomes (PRO-CTCAE) were collected daily for five weeks, and EQ-5D-5L, EORTC-QLQ-C30, weight, and analgesic use were assessed weekly for nine weeks. Co-primary endpoints were peak dysphagia (first five weeks) and ambulatory function (EQ-5D-5L mobility) at nine weeks, analyzed by Wilcoxon rank-sum test. The association between esophageal dosimetric parameters and "severe-or-worse" dysphagia was assessed. RESULTS: From May 2021-April 2024, 188 patients were randomized (standard: 92 included, 60 analyzed; esophagus-sparing: 96 included, 70 analyzed). Fourteen esophagus-sparing patients did not receive the intended intervention. These patients were recategorized as standard for per-protocol analysis. Dysphagia (any grade) occurred in 64 % (standard) and 55 % (esophagus-sparing) of patients. Intention-to-treat analysis found no differences in peak dysphagia (p = 0.20) or ambulatory status (p = 0.30). Per-protocol analysis found significant difference in peak dysphagia (p = 0.50). Dosimetric parameters (D0.027 cc-D5cc, V15Gy-V25Gy) correlated with "severe-or-worse" dysphagia. CONCLUSION: Esophagus-sparing VMAT/IMRT did not reduce peak dysphagia in the intention-to-treat analysis but showed a significant benefit in the per-protocol analysis. Higher esophageal dose and larger irradiated volumes correlated with risk of "severe-or-worse" dysphagia, suggesting that esophagus/pharynx-sparing RT may particularly benefit patients receiving high-dose, large-field radiation.
引用
- Nielsen AM, Laursen MRT, Rechner LA, et al. Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial. Radiother Oncol. 2025. PMID: 40324910. doi:10.1016/j.radonc.2025.110906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。